Ocular manifestations in a cohort of patients with mpox in the Democratic Republic of the Congo 2007–2011

TL;DR

This study reports on eye-related symptoms in patients with mpox in the Democratic Republic of the Congo, showing that nearly 8% experienced various ocular issues.

Contribution

The study provides new insights into the range of ocular manifestations associated with Clade I mpox in a specific geographic region.

Findings

Ocular manifestations were observed in 8.3% of 216 patients with mpox.

Common symptoms included conjunctivitis, eyelid lesions, and keratitis.

Some ocular manifestations could lead to serious vision-threatening complications.

Abstract

This report describes the ocular manifestations in a cohort of patients with Clade I mpox evaluated in the Democratic Republic of the Congo from 2007 to 2011, as well as the clinical course of a 3-year-old patient with mpox associated with ocular disease. Among 216 patients, ocular manifestations were observed in 8.3%, including conjunctivitis, eyelid lesions, eyelid swelling, eye pain, orbital swelling, keratitis, and corneal staphyloma. These findings highlight the broad spectrum of ocular manifestations with potentially sight-threatening consequences in patients with mpox.

Figures

Photograph of a pediatric patient in our study with diffuse facial scars from cutaneous lesions and severe corneal opacity associated with mpox (A), and photograph of another pediatric patient in our study with corneal staphyloma and fine corneal neovascularization after the acute stage of mpox (B).

An external photograph of the right eye of the 3-year-old patient demonstrates significant eyelid swelling, conjunctival edema, and diffuse deposits of white caseating material around the corneal limbus.

Full text

INTRODUCTION

Mpox, previously known as monkeypox, is a viral disease caused by the mpox virus (MPXV; also known as monkeypox virus), a double-stranded DNA virus classified within the Orthopoxvirus genus of the Poxviridae family (1). Thus far, two genetically distinct clades are known: Clade I and Clade II, with Clade I historically associated with higher morbidity and mortality than Clade II infection (2). Mpox has been known to be endemic to Central and Western Africa for decades, with Clade I infections predominantly reported in Central Africa and Clade II infections in Western Africa (3).

Clinically, mpox is typically characterized by an initial prodromal phase that includes fever, lymphadenopathy, myalgia, fatigue, and headache, followed by the development of a characteristic vesiculopustular rash that begins on the face and spreads centrifugally (3, 4). However, non-classical mpox presentation associated with sexual/intimate contacts and sustained human transmission, including asynchronous lesion development and concentrated anogenital lesion localization, has been reported with increasing frequency (5). The global spread of Clade IIb mpox beginning in May 2022 led the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC) in July 2022 (6). Although the PHEIC was lifted by May 2023, the epidemic of Clade IIb mpox continued globally, concomitant with the emergence of Clade Ib mpox, first detected in the Democratic Republic of the Congo (DRC) and subsequently spread to the neighboring countries and outside of Africa (6). The continuing spread of the epidemic prompted a renewed global PHEIC declaration in August 2024. Since 2022, more than 120,000 confirmed mpox cases have been reported worldwide, and since January 2024, more than 70,000 suspected and probable mpox cases have been reported in the DRC alone (7).

Ocular manifestations are relatively frequent in patients with mpox, and they have been reported in up to 23% of patients with Clade I mpox, predominantly affecting the ocular surface and anterior segment (8). Conjunctivitis has been the most commonly observed ocular manifestation, though severe ocular complications such as corneal ulceration, corneal perforation, or episcleritis may also occur, leading to significant visual impairment (9–11). The reported prevalence of ocular manifestations varies between 0.3% and 11% in Clade II mpox infections and 4.1%–23.1% in Clade I mpox infections. Given the ongoing global mpox epidemic, which now includes Clade Ia, Ib, and IIb infections and the potential significant ocular morbidities associated with mpox, we aim to describe the ocular manifestations associated with Clade I mpox among patients admitted to the General Hospital of Kole, Sankuru, in the DRC from 2007 to 2011, and we also detail the clinical course of a 3-year-old patient with mpox associated with ocular manifestations.

MATERIALS AND METHODS

This secondary analysis was performed to examine the spectrum of ocular manifestations in a cohort of patients with Clade I mpox in the DRC from 2007 to 2011.

The original study was a prospective observational study that was conducted at the General Hospital of Kole, located in Sankuru District, Kasai Oriental Province, DRC, from 2007 to 2011. The details of the study design have been described previously (4, 12). The region’s population primarily consists of hunters and farmers living in small villages within the tropical rainforest (12). Wild monkeys and rodents are often hunted by local communities with the risk of harboring viruses transmitted by direct contact with humors or the carcasses of animals (12). Patients who met the WHO definition of mpox (suspected case, probable case, or confirmed case) (13) and sought medical treatment at the hospital were invited to participate in the original study (4, 12). Patients were included and monitored in the original study upon obtaining positive results with pan-orthopoxvirus PCR and MPXV-specific PCR (4). Regardless of their enrollment status, all patients who met the WHO definition of mpox received the same medical management (4, 12).

A total of 216 patients were tested positive for pan-orthopoxvirus PCR and MPXV-specific PCR and were included in the original observational study (4, 12). Collected demographic characteristics, including age and sex, were analyzed for this secondary analysis. All enrolled patients underwent a comprehensive review of systems and physical examination at the time of evaluation for acute disease, and patients with ocular manifestations were reviewed and included in this secondary analysis. The clinical course of a pediatric patient with mpox associated with ocular manifestations was also reviewed and summarized here. Statistical analyses were performed using Microsoft Excel (Microsoft Corp., Redmond, WA, USA). Categorical variables were presented as frequencies, while continuous variables were represented as mean ± standard deviations.

RESULTS

Ocular manifestations in the study population

A total of 244 patients were invited to participate in the study based on the clinical diagnosis of mpox. Of these patients, a total of 216 patients were included and provided data for the study. The mean age was 14 years, with 118 patients ≥12 years of age, and 78 (36.1%) patients were female (4). Of 216 patients, 18 patients (8.3%) demonstrated ocular manifestations. The mean age of those with ocular manifestations was 13.7 ± 12.1 years, with the majority (72.2%, n = 13) being pediatric patients (<18 years of age). Eight (44.4%) patients were female. Among the 18 patients with ocular manifestations, conjunctivitis was the most common finding (n = 5, 27.8%), followed by eyelid lesions (n = 4, 22.2%), eyelid swelling (n = 3, 16.7%), eye pain (n = 3, 16.7%), orbital swelling (n = 1, 5.6%), keratitis (n = 1, 5.6%), and corneal staphyloma (n = 1, 5.6%). Among the patients with ocular symptoms, three pediatric patients (16.7%) also reported excessive tearing along with their ocular manifestations. One pediatric patient showed severe corneal opacity with diffuse facial scars from cutaneous lesions associated with mpox (Fig. 1A), and another pediatric patient demonstrated corneal staphyloma with corneal neovascularization after the acute stage of mpox (Fig. 1B). Available detailed information from one of the pediatric patients from the series is described below.

Photograph of a pediatric patient in our study with diffuse facial scars from cutaneous lesions and severe corneal opacity associated with mpox (A), and photograph of another pediatric patient in our study with corneal staphyloma and fine corneal neovascularization after the acute stage of mpox (B).

Case report

A 3-year-old girl presented to the General Hospital of Kole with an acute onset of fever of 6 days duration and a vesicular rash 3 days prior. Past medical history included an unspecified diarrheal disease, and past surgical history was unremarkable. Dietary history was notable for Gambian rat consumption within 6 months of presentation. She had been vaccinated against measles but had never received vaccinations for varicella zoster. Physical examination revealed eyelid edema with excessive tearing, cervical adenopathy, and numerous pustular lesions consistent with the diagnosis of mpox. Skin lesion count revealed a total of 141 lesions at various stages of healing, with the majority of lesions localized to the head and facial regions. An external photograph of the right eye demonstrated significant eyelid swelling and conjunctival edema with deposits of whitish caseating material around the corneal limbus (Fig. 2). The patient was admitted to the mpox isolation unit for further management.

An external photograph of the right eye of the 3-year-old patient demonstrates significant eyelid swelling, conjunctival edema, and diffuse deposits of white caseating material around the corneal limbus.

The patient underwent a comprehensive work-up including comprehensive metabolic panel (CMP), complete blood count (CBC) with differential, and urinalysis. In addition, a blood draw and oropharyngeal swab were collected for MPXV PCR testing. CBC showed anemia, with a hematocrit level of 27% and a normal white blood cell count, and CMP was unremarkable. PCR testing was positive for MPXV in both blood and oropharyngeal swab samples. The longitudinal PCR results from the blood draw and oropharyngeal swab samples are summarized in Fig. S1. Urinalysis revealed moderate protein and bilirubin with elevated urobilinogen.

The patient was treated empirically for her ophthalmic findings with topical ophthalmic agents, including chloramphenicol, tetracycline, ofloxacin, indomethacin, and atropine. Additionally, she also received prophylactic oral amoxicillin for secondary bacterial infections and potassium permanganate for skin lesions. The eyelid edema resolved by day 9 of the hospitalization; however, the patient demonstrated persistent narrowing of the palpebral fissure following the resolution of eyelid edema. By the time of discharge on day 15, the majority of skin lesions had resolved, and the patient was discharged in stable condition. The narrowing of the palpebral fissure was still present on day 20 follow-up visit; however, it had resolved on day 75 follow-up visit. She remained clinically stable on day 75 follow-up visit.

DISCUSSION

This retrospective analysis of a landmark clinical characterization study in DRC (2007–2011) highlights the broad spectrum of ocular manifestations in patients with Clade I mpox, underscoring the potential for significant visual morbidity. Among 216 patients included in the original prospective study, we observed that 18 patients (8.3%) demonstrated ocular manifestations at the time of initial examination, with conjunctivitis being the most common finding in this cohort, which is consistent with other reports in the literature (8, 9). While follow-up for the patients with ocular manifestations in our study was not available, recent evidence from the literature has shown that keratitis may lead to significant visual morbidity from complications, including corneal scarring, neovascularization, and perforation (9–11). Moreover, secondary ocular complications such as bacterial infections or periorbital soft tissue infections can occur in the settings of keratitis and eyelid lesions, respectively. The patient described in this article demonstrated persistent narrowing of the palpebral fissure following the initial presentation with eyelid swelling and periorbital inflammation, illustrating the potential devastating effects of ocular manifestations in patients with mpox.

Notably, the majority of patients with ocular manifestations in our secondary analysis were pediatric patients with a mean age of 8.0 ± 5.5 years. Whether mpox may lead to a greater burden of ocular disease in pediatric patients warrants further studies, as other studies have reported a disproportionate number of pediatric patients with ocular manifestations compared to adult patients (8, 9). Among 282 mpox patients described by Jezek et al*., more than 60% of patients were <15 years of age, and conjunctivitis was commonly reported, while keratitis was noted in 11 (4.4%) patients (9). Among these pediatric patients, one 4-year-old girl experienced bilateral blindness, three children reported unilateral blindness, and six other children reported various degrees of visual impairment due to corneal opacities (9). Hughes et al.* also reported 23.1% of patients with conjunctivitis in a cohort of 68 patients, with 61.8% of patients less than 10 years old. Notably, the patients described in these two studies were affected by the Clade I variant, which tends to be associated with a higher morbidity than the Clade II variant (3, 8, 9). With the ongoing circulation of Clade I MPXV and given the risks of visual impairment in children with mpox, health care providers should be aware of ocular complications when evaluating children with mpox. Prompt referrals to an ophthalmologist should be made to prevent visual loss in pediatric patients, who are also at a high risk of developing amblyopia.

The pathogenesis of ocular manifestations in patients with mpox remains poorly understood; however, recent evidence from cases of mpox-associated ocular disease has shown signs of persistence of MPXV genomes within extra- and intraocular fluid that could play a role in disease pathogenesis (11, 14). Other studies reported the persistence of MPXV genomes within the ocular surface and aqueous humor samples at 145 days and 8 months, respectively, after the acute infection (14, 15). Our patient demonstrated the detection of viral particles in blood on day 21 and in oropharyngeal mucosa on day 15. Whether the presence of viral particles within the oropharyngeal mucosa reflects the ocular surface mucosa is unknown. However, the relationship of viral genomes within varying mucosal tissues requires further study. Further studies are also needed to understand the persistence of MPXV genomes within the ocular surface and intraocular fluid, as well as their contribution to the pathogenesis of ocular manifestations associated with mpox.

This study is limited by its retrospective nature, lack of visual acuity assessment and slit-lamp biomicroscopic evaluation, and the resource constraints of the study setting. The remote location of this study, with limited ophthalmic services, made the detailed assessment difficult. Nonetheless, external photographic documentation was able to capture severe ophthalmic disease likely associated with vision impairment in patients with mpox. As Clade I mpox was circulating in Kole, DRC, at the time of this report, further study of both Clade Ia and Ib mpox in the ongoing outbreak is particularly relevant for vision health and quality of life for patients with mpox among patients under 18 years old, as they might be at higher risk. The broad spectrum of ocular manifestations, including conjunctivitis, keratitis, and periorbital manifestations in patients with mpox, highlights the breadth of ophthalmic subspecialty care and management required. These resource requirements may be particularly challenging within resource-limited settings where mpox transmission has been documented. Heightened surveillance measures with further research for ocular manifestations associated with mpox remain critical, given the expanding number of cases in the DRC, neighboring countries in sub-Saharan Africa, and countries previously unaffected by mpox that have recently reported Clade I mpox.